CPRX ▾TradingViewOVTLYR consoleNews (1w)Earnings search — Catalyst Pharmaceuticals, Inc.

Healthcare · ETF XLV · as of 2026-07-14

Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Catalyst Pharmaceuticals, Inc. NCM
Healthcare · Biotechnology
Market cap
3.5B
P/E (TTM)
18.7
EPS (TTM)
1.68
Employees
-
IPO
-
Website
-

Price & today

$31.49 ATR(14) 0.08 (0.25%)
Stock today+0.03%
Sector ETF today+0.52%
Residual (stock-specific)-0.49%

Sector correlation

20-day correlation with XLV0.27
60-day correlation with XLV0.23
Status normal

Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.

Technicals

10 EMA$31.47
20 EMA$31.40
50 EMA$30.54
EMA stackBULLISH
RSI(14)70.2 overbought
52-week high distance-3.29%
52-week low distance+65.30%

Signals

Market F&G44.9
Bull%13.8%
OVTLYR status SELL (48d)
Sector rank—
Next earnings —
TradingView OVTLYR console More news (Google) Sector dashboard (XLV)

MarketSmith metrics - our compute

RS Rating
-
ADR%
0.1
RMV (tight)
3.0
Ext (ATR>20EMA)
-
Rel Vol
570.0%
U/D 50d
1.82
U/D 25d
2.17
Accum/Dist 25d
1 / 0
EPS YoY
+19.0%
LoD dist
-
Off 52w High
3.3%
Above 52w Low
65.3%
1W / 1M
+0.0 / +0.4
Avg $Vol 50d
84.8M
Mkt Cap (B)
-
Trend 8/8
no
Sector XLV
+1.3% 1W
Base len (VCP)
7wk (6/21)
Coil (base shape)
85TVPX
What do these abbreviations mean?
RS Rating
- IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
ADR%
- average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
RMV (tight)
- Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
Ext (ATR>20EMA)
- how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
Rel Vol
- latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
U/D 50d / 25d
- up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
Accum/Dist 25d
- heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
LoD dist
- close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
Off/Above 52w
- trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
Trend 8/8
- all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
Base len (VCP)
- weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.

Fundamentals & valuation - reference, not entry inputs

P/E (TTM)
18.7
Fwd P/E
10.0
PEG
-
Price/Book
3.7
Profit margin
36.4%
ROE
25.5%
Debt/Equity
0.3
Rev growth
+7.6%
Analyst target
$34 (+8%)
Analyst rating
STRONG_BUY
Institutional %
89.0%
Insider %
5.6%
Float %
-
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.

Company data - context read, not entry inputs

Industry rank
33 / 146
Industry
Biotechnology
Float
114.5M
Float turnover 20d
2.5%
Avg $Vol 20d / 50d
89.5M / 84.8M
Days to cover
7.2
Short % float
8.9%
Institutional %
89.0%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.

Quarterly EPS - earnings acceleration

A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.

QuarterEPS ($)%Chg YoYSales ($M)%Chg
Feb-24 0.29 +32% 110.6 +82%
May-24 0.38 +46% 98.5 +15%
Aug-24 0.56 +70% 122.7 +23%
Nov-24 0.57 - 128.7 +25%
Feb-25 0.70 +141% 141.8 +28%
May-25 0.68 +79% 141.4 +44%
Aug-25 0.68 +21% 146.6 +19%
Nov-25 0.68 +19% 148.4 +15%
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).

Recent news - our DB (Finnhub + OVTLYR)